When Cancer Moves Beyond the Bones
For many men with metastatic castration-resistant prostate cancer (mCRPC), cancer first spreads to the bones. But for some, imaging eventually shows it has reached the liver, lungs, or both. Doctors call this visceral metastasis.
If this describes your situation, you likely have urgent questions. Can Lu-177 PSMA therapy still help? Does organ spread change your eligibility? What does your care team need to reassess before making a plan?
This article answers those questions, based on evidence from major clinical trials and published research. You'll go into your next appointment informed and ready to ask the right questions.
What Visceral Metastases Mean in Prostate Cancer
The word "visceral" refers to internal organs outside the skeleton. In mCRPC, the most common visceral sites of spread include the liver, the lungs, the adrenal glands, and the lining of the abdomen (the peritoneum).
Bone and lymph node spread is more common early on. Visceral spread - especially to the liver - tends to occur later and often shows a more aggressive form of the disease. A review published in PMC examining prostate cancer liver metastasis describes liver spread as an ominous site that responds less well to standard hormonal therapies than bone or lymph node disease does.
That said, visceral spread doesn't close all options. It does mean your treatment plan needs a careful, thorough review by a specialist team.
How Lu-177 PSMA Therapy Works
Lu-177 PSMA is a radioligand therapy. It pairs a radioactive molecule of lutetium-177 with a targeting molecule that binds to PSMA - a protein found on the surface of most prostate cancer cells. Once the drug attaches to a cancer cell, it delivers focused radiation directly to that cell from the inside.
Crucially, Lu-177 PSMA travels through the bloodstream. It doesn't stay in one place. It seeks out PSMA-expressing cancer cells wherever they are in your body - in bones, lymph nodes, and organs like the liver and lungs. That's why doctors have studied whether Lu-177 PSMA can treat cancer in organs as well as bones.
The brand name approved in the United States is Pluvicto. It received FDA approval in 2022 for progressive PSMA-positive mCRPC in patients who had already received androgen receptor pathway inhibitor (ARPI) therapy and taxane-based chemotherapy.
Does Liver or Lung Spread Disqualify You from Lu-177 PSMA Therapy?
The short answer is: not automatically.
Having cancer in the liver or lungs doesn't rule out Lu-177 PSMA therapy. The landmark VISION trial - which established the clinical evidence base for FDA approval - enrolled patients with liver metastases. Liver spread was tracked as a key clinical factor, but it didn't exclude patients. Published VISION trial data confirm that patients with visceral disease were part of the treated population.
The true eligibility requirement is about PSMA expression, not tumor location. To qualify for Lu-177 PSMA therapy, you generally need to meet these criteria:
- A current PSMA PET scan showing PSMA-positive disease, with at least one lesion showing uptake greater than the normal liver signal
- Prior treatment with at least one ARPI therapy and taxane-based chemotherapy
- Adequate organ function - kidney, liver, and bone marrow results must meet defined safety thresholds
- A confirmed prostate cancer diagnosis with evidence of metastatic spread
If your liver or lung lesions are PSMA-positive - meaning they light up on a PSMA PET scan - those lesions can be targeted by Lu-177 PSMA. Problems occur when visceral lesions no longer show PSMA expression, which can happen in more aggressive or later-stage tumors.
The PSMA PET Scan - The Test That Shapes Your Options
For men with visceral spread, the PSMA PET scan is the most important step in the eligibility process. It tells your care team two critical things:
- Whether your bone, lymph node, and organ lesions are PSMA-positive
- Whether any lesions - especially in the liver or lungs - have lost PSMA expression and may not be reached by the therapy
PSMA expression can differ between lesions in the same person. Some patients develop what oncologists call PSMA heterogeneity - some tumors express PSMA, others do not. Visceral metastases sometimes show lower PSMA uptake than bone lesions. If your liver or lung lesions aren't lighting up on the scan, the therapy won't reach those specific lesions, and your team will need to factor that into your plan.
That's why a recent PSMA PET scan is needed before any eligibility decision is final. Our guide explains how to read your PSMA PET scan results and what they mean for your Lu-177 eligibility.
What Clinical Evidence Says About Lu-177 PSMA and Visceral Disease
Research on this patient group is growing. Researchers studying mCRPC patients with liver metastases who received Lu-177 PSMA-617 therapy found it may produce PSA responses and partial regression of liver lesions in some patients. Patients who completed more cycles showed better biochemical responses and better results on follow-up imaging.
At the same time, researchers confirmed that liver metastases worsen the prognosis. Patients with liver spread have shorter median progression-free survival compared to patients without organ spread. This is due to the cancer's biology, not the therapy's limitations.
A multivariable analysis of the VISION trial, published in PMC, found liver metastases in the model predicting progression-free survival outcomes. This shows liver involvement affects expected outcomes but doesn't exclude patients.
Lung metastases present a different picture. Lung spread generally has a better prognosis than liver spread. PSMA expression in lung lesions is usually preserved. Specialists report that patients with spread only to the lungs may respond well to Lu-177 PSMA if scans show adequate PSMA uptake.
What Changes in Your Treatment Plan When Visceral Metastases Are Present
When cancer has spread to an organ, your care team will approach treatment planning differently in several concrete ways.
More thorough pre-treatment assessment. Your doctor will check liver function tests (ALT, AST, and bilirubin) before therapy starts. Lu-177 PSMA is processed through the liver. If tumor burden is high, your team checks whether your organ function is safe enough to proceed.
Closer monitoring between cycles. Blood tests happen before each cycle to track liver, kidney, and blood cell function. With organ involvement, your team may do extra checks if results look concerning.
Discussions about treatment sequencing. Your oncologist may discuss whether to try a different treatment first or move forward with Lu-177 PSMA. There's no single right answer for every patient. A second opinion from a nuclear medicine specialist can help at this point.
An honest conversation about treatment goals. With organ spread, your team should discuss what success means for you - slowing the cancer, improving how you feel, reducing pain, or keeping your quality of life. These goals matter and are possible, even with advanced cancer.
To learn what baseline factors predict your treatment response, see our guide on baseline factors that predict Lu-177 PSMA response in mCRPC.
Side Effects and Safety Considerations with Visceral Disease
Lu-177 PSMA commonly causes dry mouth, fatigue, nausea, low blood counts, and kidney stress. All patients receiving therapy may experience these.
When liver metastases are present, liver-related toxicity from the therapy is understandable to worry about. Studies find that severe liver damage from Lu-177 PSMA is rare. The main risk to liver function comes from the tumor itself, not the drug.
Your care team sets specific limits for liver enzymes and bilirubin before each cycle. If levels go outside safe ranges, treatment pauses until they stabilize. This protects your organ function during your full treatment.
What International Patients Should Expect
Men from the United Kingdom, Australia, Canada, the United States, Germany, the UAE, New Zealand, and other countries travel to India for Lu-177 PSMA therapy. Several nuclear medicine centers there offer the treatment for much less than Western hospitals charge. If you have organ metastases, here are practical steps for planning.
Your imaging must be current. A PSMA PET/CT scan (typically Ga-68 PSMA) from the past two to three months is needed for eligibility review. If your most recent scan was before your liver or lung lesions were found, you'll need a new scan before doctors decide eligibility.
Your complete medical records matter. Your doctors need a full picture of your case - all prior therapies, pathology reports, previous scans, and current blood tests. With advanced cancer, complete records help doctors plan the right treatment.
Your functional fitness is assessed. Patients with organ spread sometimes feel tired, lose appetite, or lose strength. Your performance status - how well you function in daily life - is part of eligibility review, and doctors use it to schedule your cycles.
Cycle scheduling may be adjusted. According to FDA prescribing information for Pluvicto, Lu-177 PSMA therapy typically means up to six cycles about six weeks apart. With organ spread, your team may order scans or blood tests after early cycles to decide whether to continue.
For details on planning treatment in India, including documents and travel scheduling, see: Planning your Lu-177 PSMA treatment cycle in India - a guide for international patients.
When to Talk to Your Doctor
If your prostate cancer has spread to the liver or lungs and you're considering Lu-177 PSMA therapy, here are good questions to ask your doctor:
- Is my visceral disease PSMA-positive on my current PSMA PET scan?
- Do my liver function tests meet the safety requirements for Lu-177 PSMA?
- Has my case been assessed by doctors with Lu-177 PSMA experience?
- Would a second opinion from a nuclear medicine specialist help clarify my options?
- What should I realistically expect given my specific cancer spread?
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your situation.
Frequently asked questions
Can I still get Lu-177 PSMA therapy if my prostate cancer has spread to my liver?
Yes, liver spread does not automatically disqualify you. The key requirement is that your lesions - including liver lesions - show PSMA expression on a current PSMA PET scan. If your liver lesions are PSMA-positive, they may be targetable with Lu-177 PSMA. Your care team will also review your liver function blood tests to confirm that it is safe to proceed. The VISION trial, which provided the evidence base for FDA approval of this therapy, included patients with liver metastases in the treated population.
Are treatment outcomes worse with Lu-177 PSMA if I have liver metastases compared to bone metastases only?
Research suggests that patients with liver metastases tend to have shorter progression-free survival compared to those with bone-only disease. This reflects the more aggressive biology of visceral spread in advanced prostate cancer - not a specific problem with how Lu-177 PSMA works. Clinical studies have shown that some patients with liver metastases do achieve meaningful PSA responses and partial tumor regression from the therapy, particularly those who are able to complete multiple treatment cycles.
What if my lung or liver lesions are PSMA-negative on the scan but my bone lesions are PSMA-positive?
This is a situation your care team will need to assess carefully. Lu-177 PSMA will not effectively reach lesions that do not express PSMA, even while it may treat PSMA-positive lesions elsewhere in your body. Your oncologist may discuss whether combining Lu-177 PSMA with another therapy that can address PSMA-negative lesions makes sense, or whether a different treatment sequence is more appropriate for your case. A second opinion from a specialist center is often helpful in this type of mixed-result situation.
Do I need a new PSMA PET scan if my cancer has recently spread to a new organ site?
Yes. Disease that has spread to a new site - especially an organ - may show different PSMA expression than lesions found on your earlier scans. A current PSMA PET scan, generally done within two to three months before starting therapy, is important for accurate eligibility assessment. This is especially true when visceral sites like the liver or lungs are newly involved, because PSMA expression at those sites directly determines whether the therapy can effectively reach those tumors.
What blood tests does my team use to check if my liver can tolerate Lu-177 PSMA therapy?
Your care team will typically check liver enzymes including ALT and AST, bilirubin levels, and albumin. They will also assess kidney function through creatinine and estimated GFR, and check full blood counts covering red blood cells, white blood cells, and platelets. These tests are done before each treatment cycle to ensure your body is handling the therapy safely and that your liver function remains within acceptable ranges throughout your treatment course.
Is Lu-177 PSMA available in India for men whose prostate cancer has spread to the liver or lungs?
Yes. Established nuclear medicine centers in India offer Lu-177 PSMA therapy for eligible mCRPC patients, including those with visceral disease. Eligibility is assessed individually based on your most recent PSMA PET scan, liver function blood results, prior treatment history, and overall physical fitness. Submitting your medical records - including your PSMA PET/CT report, pathology report, full treatment history, and current blood results - for specialist review is the first step in determining whether you qualify and what a treatment plan could look like for your case.